TLDR
- The U.S. government finalized a 2.48% average increase in 2027 Medicare Advantage payments, far better than the 0.09% January proposal
- Including risk-assessment payment changes, the total increase is expected to be around 5%
- UNH stock rose in premarket trading following the news
- Wall Street holds a Moderate Buy consensus, with 18 Buy ratings and an average 12-month price target of $364.63
- UnitedHealth’s 2025 revenue showed UnitedHealthcare up 16% to $344.9B and Optum up 7% to $270.6B
The government’s April 7 decision on Medicare Advantage rates is being seen as a meaningful relief for UnitedHealth after a rough stretch for the stock.
UnitedHealth Group Incorporated, UNH
Rising medical costs in the Medicare Advantage business have weighed on UNH for several years. The January proposal of just a 0.09% rate increase rattled investors and added to concerns about how long margin pressure could last.
The final rate of 2.48% — with the total increase reaching around 5% when risk-assessment changes are included — landed well above expectations. Analysts said it should help the sector manage medical-cost trends more effectively.
UNH moved higher in premarket trading on the news.
Scale That Still Matters
UnitedHealth’s 2026 outlook puts UnitedHealthcare revenue above $335 billion and Optum above $257.5 billion. That’s not a company in retreat.
The 2025 numbers backed that up. UnitedHealthcare revenue grew 16% to $344.9 billion. Optum rose 7% to $270.6B. The core business is still growing, even with the margin headwinds.
The combination of insurance, pharmacy, care delivery, and data infrastructure gives UnitedHealth a platform that’s hard to replicate. That’s still the foundation of the bull case.
What Wall Street Thinks
According to MarketBeat, UNH carries a Moderate Buy consensus rating. The breakdown: 1 Strong Buy, 18 Buy, 7 Hold, and 2 Sell ratings from analysts.
The average 12-month price target across 29 analysts sits at $364.63, which implies roughly 29.55% upside from recent levels.
That’s not a Wall Street community writing the company off. But the hold and sell ratings show that analysts want to see proof — better cost control and steadier execution — before going all-in again.
Medicare Advantage cost pressure has been the central issue. The government’s rate decision this week doesn’t erase that concern, but it does change the math heading into 2027.
Valuation has also shifted. UNH no longer trades at the premium multiple it once commanded as the go-to managed care name. That reset creates more room for upside if the cost environment begins to stabilize.
The improved Medicare Advantage payment rate is the most recent development in that story.
Final thoughts
UnitedHealth stock no longer looks like a simple defensive-growth holding. It now looks more like a recovery name with a strong underlying franchise. The business still has huge scale and multiple growth engines, but investors need to see better cost control, steadier execution, and renewed confidence in management’s outlook.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
